2 completed, 1 recruiting. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Streptococcus Pneumoniae Infection: new trials by email Literature Review of Streptococcus Pneumoniae Infection trials Research Report on Streptococcus Pneumoniae Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M) - Streptococcus Pneumoniae Infection | Phase 1 / Phase 2 | Recruiting | CanSino Biologics Inc. | 854 | 2026-05-24 | 2026-08-05 |
| CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study PCV13 - Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection | Phase 2 / Phase 3 | Completed | University of British Columbia | 248 | 2018-08-23 | 2024-03-04 |
| Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) Prevnar 13®, V114 1x:1x:1x, V114 2x:2x:2x - Streptococcus Pneumoniae Infection, Pneumococcal Infections | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 341 | 2014-01-28 | 2019-06-24 |
Bacterial Infections (3) · Bacterial Infections and Mycoses (3) · Gram-Positive Bacterial Infections (3) · Infections (3) · Streptococcal Infections (3)
13-valent pneumococcal vaccine (3) · CRM197 (non-toxic variant of diphtheria toxin) (1) · Protons (1) · Referral and Consultation (1) · Tetanus Toxoid (1)
CanSino Biologics Inc. (1) · Merck Sharp & Dohme LLC (1) · University of British Columbia (1)
Canada (1) · China (1)
Manish Sadarangani, MD (1) · Zhiqiang Xie, Master (1)